ClinicalTrials.gg
CompletedNCT07222254Updated Aug 20, 2026

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of AZD0292 in Healthy Japanese Participants

A Phase 1 interventional study of AZD0292 and Placebo in Healthy Participants, sponsored by AstraZeneca. Completed at 1 site in Japan. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics (PK) of single ascending doses of AZD0292 administered via intravenous (IV) infusion in healthy Japanese participants.

Read the detailed description

This is a Phase I, randomized, double-blind, placebo-controlled, single ascending dose study in healthy Japanese participants to investigate 2 dose levels of AZD0292. Participants will be randomized to receive either AZD0292 or placebo, proceeding with sentinel cohorts.

The study will comprise:

  • A Screening Period of maximum 28 days.
  • A Treatment Period during which participants will be resident at the site from the day before study intervention administration (Day -1) until at least 24 h post-EOI with study intervention; and discharged on Day 2.
  • A Follow-up Period from Day 3 to Day 16.
  • An extended Follow-up Period from Day 17 to Day 161.
02

Conditions studied

  • Healthy Participants

Keywords

  • Monoclonal antibody
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy Japanese participants with suitable veins for cannulation or repeated venipuncture.
  • Women of (WOCBP) must have a negative pregnancy test and must not be lactating.
  • Participants must agree to use an approved method of highly effective as defined in the protocol.
  • Have a (BMI) between 18 and 32 kg/m2 inclusive and weigh at least 45 kg at screening.

Exclusion criteria

Exclusion Criteria:

  • History of any disease or disorder which may either put the participant at risk because of participation in the study, or influence the results or the participant's ability to participate in the study.
  • History or presence of gastrointestinal, hepatic, or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
  • History of , other than treated non-melanoma skin cancers or locally-treated cervical cancer, in the previous 5 years.
  • Any clinically important illness, chronic infections or individuals who are at increased risk of infection.
  • History of acquired or inherited immunodeficiency disorders.
  • History of severe coronavirus disease 2019 (COVID-19) infection requiring hospitalization within the last 12 months or clinical history compatible with ongoing long COVID-19.
  • Current smokers or those who have smoked or used nicotine products within the previous 6 months prior to screening.
  • History of alcohol or drug abuse within the past 2 years.
  • History of severe allergy/ or ongoing clinically important allergy/hypersensitivity, as judged by the PI or history of hypersensitivity to drugs with a similar chemical structure or class to AZD0292 and contained in AZD0292.
  • Known hypersensitivity to antihistamines.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    AZD0292 Dose Level 1

    Participants will receive AZD0292 (dose level 1) or matching placebo on Day 1.

    Drug: AZD0292 · Drug: Placebo

  • Experimental
    AZD0292 Dose Level 2

    Participants will receive AZD0292 (dose level 2) or matching placebo on Day 1.

    Drug: AZD0292 · Drug: Placebo

Interventions

  • Single dose of AZD0292 will be administered as an IV infusion.

  • DrugPlacebo

    Single dose of placebo will be administered as an IV infusion.

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AEs), serious adverse events (SAEs) and adverse event of special interest (AESI)

    To assess the safety and tolerability of AZD0292 following IV administration of single ascending doses to healthy Japanese adult participants.

    Time frame: Up to Extended Follow-up Period (Day 161)

Secondary outcomes

  1. Maximum observed drug concentration (Cmax)

    To characterize the Cmax of AZD0292 following administration of single ascending doses of AZD0292 to healthy Japanese adult participants.

    Time frame: From Day 1 to Extended Follow-up Period (Day 161)

  2. Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast)

    To characterize the AUClast of AZD0292 following administration of single ascending doses of AZD0292 to healthy Japanese adult participants.

    Time frame: From Day 1 to Extended Follow-up Period (Day 161)

  3. Area under concentration-time curve from time 0 to infinity (AUCinf)

    To characterize the AUCinf of AZD0292 following administration of single ascending doses of AZD0292 to healthy Japanese adult participants.

    Time frame: From Day 1 to Extended Follow-up Period (Day 161)

  4. Number of participants with positive anti-drug antibodies (ADAs) to AZD0292 in serum

    To evaluate the ADA responses following administration of single ascending doses of AZD0292 to healthy Japanese adult participants.

    Time frame: From Day 1 to Extended Follow-up Period (Day 161)

07

Study locations

1 site
  • Research Site
    Sumida-ku, 130-0004, Japan
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2025 to primary completion in Jul 2026, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2025
First posted
Oct 29, 2025
StartActual
Dec 12, 2025
Primary completionActual
Jul 30, 2026
CompletionActual
Jul 30, 2026
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07222254
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Oct 29, 2025
Start date
Dec 12, 2025
Primary completion
Jul 30, 2026
Completion
Jul 30, 2026
Last update
Aug 20, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AZD0292

Start the discussion